查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2128967

肢端肥大症治療市場：依產品類型、給藥途徑、通路、療法、國家及地區分類－全球產業分析、市場規模、市場佔有率及2026年至2033年預測

Acromegaly Treatment Market, By Product Type, By Route of Administration, By Distribution Channel, By Treatment Type, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
出版日期: | 出版商: AnalystView Market Insights | 英文 301 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2025 年，肢端肥大症治療市場價值將達到 18.076 億美元，並預計從 2026 年到 2033 年將以 6.5% 的複合年成長率成長。

肢端肥大症治療市場涵蓋了廣泛的藥物療法和治療監測，旨在支持在手術不適用、失敗或無效時進行生化控制。此治療的關鍵產品包括生長抑制素類似物、生長激素受體拮抗劑、多巴胺促效劑和新型內分泌療法。現今，治療方案的選擇更加明確，主要依據IGF-1反應率、腫瘤特徵、耐受性、治療複雜性、給藥負擔和既往治療經驗等參數。儘管到2025年，各類藥物的治療選擇仍然豐富，但隨著帕佐汀（parzsotin）在美國獲得FDA批准，口服給藥在市場上的重要性日益凸顯。生長抑制素類似物、多巴胺促效劑和培維索孟（pegvisomants）均已獲得FDA批准。因此，市佔率不再取決於治療方案的數量，而是取決於療效、便利性和個人化。

肢端肥大症治療市場—市場動態

口服給藥方式正在重塑治療的便利性和產品競爭格局。

短期內，推動市場成長的一大動力是口服製劑治療方案的普及，這類藥物的服用方式更為方便。 2025年9月，FDA批准了帕洛托汀（palotothotin），這是第一個用於治療成人肢端肥大症的每日一次口服藥物。 FDA的核准是基於兩項大型III期臨床試驗，這兩項試驗共納入了來自18個國家73個研究中心的169名患者，結果證實了該藥物的療效。在24週時，治療組和另一項試驗中生化指標控制率分別為56%和83%，而安慰劑組的相應比例分別為5%和4%。因此，憑藉每日一次的便捷給藥方式，該藥物的商業性成功勢頭強勁，並對市面上其他注射類藥物構成了挑戰。在此背景下，給藥的便捷性仍然是至關重要且不斷發展的競爭因素。

肢端肥大症治療市場－市場區隔分析：

全球肢端肥大症治療市場按產品類型、給藥途徑、分銷管道、治療類型和地區進行細分。

就產品類型而言，生長激素受體拮抗劑主要用於其他藥物無法控制生化指標的病例，例如培維索孟透過抑制生長激素受體來降低IGF-1水平。生長抑制素受體促效劑是藥物治療的主要類別，因為它們可以抑制生長激素的分泌，但多巴胺促效劑的使用通常僅限於特定人群，因為它們對許多患者的療效較差。口服生長抑制素受體促效劑帕佐汀（商品名：帕索尼）在獲得FDA批准後於2025年上市。該藥物的核准為對手術無反應或不適合手術的肢端肥大症成年患者提供了一種每日一次的口服藥物。

從給藥途徑來看，臨床實驗室檢查是肢端肥大症診斷的主要組成部分，其中IGF-1水平用於篩檢，生長激素抑制試驗用於確診。同樣，影像學檢查也是評估的重要組成部分，通常使用MRI來觀察腦下垂體並確定腫瘤的大小和位置。臨床實驗室檢查和影像學檢查相輔相成，前者評估荷爾蒙水平以確診，後者則識別腫瘤的特徵。 2025年，在FDA核准的Paltosotin臨床試驗中，IGF-1水準被用作評估生化治療反應的主要指標。因此，臨床實驗室檢查是肢端肥大症評估的基礎，並指南臨床醫生選擇藥物治療方案。

肢端肥大症治療市場—區域分析

北美憑藉著成熟的內分泌療法、積極的監管活動、專業的醫療保健體係以及創新療法的商業化，繼續保持其作為主要市場的地位。尤其值得一提的是，2025年9月，FDA在完成兩項III期主要臨床試驗（涉及18個國家73個研究中心的169名患者）後，批准了Paltosotin上市。這標誌著FDA批准的首個用於治療肢端肥大症的每日一次口服療法問世。據Crinetics公司稱，在產品上市期間，其銷售團隊聯繫了超過95%的主要保險公司和目標醫生。這種以專家為中心的策略使該公司建立了強大的市場地位。因此，北美仍是創新便捷療法的重要樞紐。

歐洲是一個重要的市場，這得益於其完善的治療中心和專家網路，以及成熟長效生長抑制素類似物的供應。據益普生公司稱，截至2025年底，Somatrin Autogel/Depot已在全球約70個國家銷售。該公司還報告稱，2025年北美佔Somatrin銷售額的52.1%，凸顯了歐洲在全球供應和分銷網路中的地位，而非作為一個獨立的區域市場。因此，歐洲市場主要受多種因素影響，例如治療專家的數量、現有注射療法的使用情況以及對更便捷治療方案的需求。

目錄

第1章 肢端肥大症治療市場概覽

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章 肢端肥大症治療的主要市場趨勢

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 未來市場趨勢

第4章：肢端肥大症治療產業分析

  • PEST分析
  • 波特五力分析
  • 市場成長前景展望圖
  • 管理體制分析

第5章：肢端肥大症治療市場：地緣政治張力加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章 肢端肥大症治療市場概況

  • 2025年肢端肥大症治療市佔率分析
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

第7章：肢端肥大症治療市場：依產品類型分類

  • 概述
    • 基於細分市場的市場佔有率分析：按產品類型
    • 生長激素受體拮抗劑
    • 生長抑制素類似物
    • 多巴胺促效劑
    • 其他

第8章：肢端肥大症治療市場：依給藥途徑分類

  • 概述
    • 按給藥途徑分類的市佔率分析
    • 注射藥物
    • 口服

第9章：肢端肥大症治療市場：依通路分類

  • 概述
    • 基於細分市場的市場佔有率分析：按分銷管道分類
    • 零售藥房
    • 醫院藥房
    • 網路藥房

第10章：肢端肥大症治療市場：依治療類型分類

  • 概述
    • 基於細分市場的市場佔有率分析：按治療類型
    • 藥物治療
    • 外科手術
    • 放射線治療

第11章 肢端肥大症治療市場：依地區分類

  • 介紹
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 主要製造商：歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 丹麥
    • 其他歐洲國家
  • 亞太地區
    • 概述
    • 主要製造商：亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 台灣
    • 越南
    • 其他亞太國家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他拉丁美洲國家
  • 中東和非洲
    • 概述
    • 主要生產商：中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 伊朗
    • 卡達
    • 其他中東和非洲國家

第12章：主要供應商分析：肢端肥大症治療產業

  • 競爭基準
    • 競爭對手儀錶板
    • 競爭定位
  • 公司簡介
    • Novartis AG
    • Ipsen Biopharmaceuticals, Inc.
    • Pfizer Inc.
    • Recordati SpA
    • Chiesi Farmaceutici SpA
    • Crinetics Pharmaceuticals, Inc.
    • Camurus AB
    • Ionis Pharmaceuticals, Inc.
    • Sun Pharmaceutical Industries Ltd.
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co., Inc.
    • Wockhardt Ltd.
    • Dauntless Pharmaceuticals
    • GlaxoSmithKline plc
    • Cipla Ltd.
    • Others

第13章：AnalystView 的全景視圖

簡介目錄
Product Code: ANV7350

Acromegaly Treatment Market size was valued at US$ 1,807.6 Million in 2025, expanding at a CAGR of 6.5% from 2026 to 2033.

The acromegaly treatment market comprises a wide range of drug therapies and therapy monitoring that aids biochemical control when surgery may not be appropriate, unsuccessful, or ineffective. The key products used in its treatment are somatostatin analogs, growth hormone receptor antagonists, dopamine agonists, and newer endocrine therapies. The choice of treatment is now more firmly directed by parameters such as the rate of response in terms of IGF-1, tumor characteristics, tolerability, complexity, burden of dosing, and past treatment experience. In 2025, therapeutic choices remain broad class-wise, while oral delivery has increased market significance after the FDA approval of paltusotine for use in the USA. Somatostatin analogs, dopamine agonists, and pegvisomant are a few of those recorded by the FDA as therapies. Therefore, market share is no longer about offering treatments but about effectiveness, convenience, and individuality.

Acromegaly Treatment Market- Market Dynamics

Oral Administration Is Reshaping Treatment Convenience and Product Competition

A strong near-term driver is the trend toward less burdensome administration via an oral formulation. In September 2025, the FDA approved paltusotine, the first once-daily oral therapy for the treatment of acromegaly in adult patients. The FDA approval was based on two pivotal phase III trials, which enrolled 169 patients across 73 centers in 18 countries, demonstrating the drug's efficacy: biochemical control at week 24 was achieved in 56% of treated patients in one trial and 83% in another, compared to 5% and 4% with placebo, respectively. As a result, the commercial success of convenient once-daily dosing gained significant momentum, creating a challenge for other injectable agents on the market. In this context ease of administration is a relevant and evolving competitive factor.

Acromegaly Treatment Market- Segmentation Analysis:

The Global Acromegaly Treatment Market is segmented on the basis of Product Type, Route of Administration, Distribution Channel, Treatment Type, and Region.

By product type, the growth hormone receptor antagonists are mainly indicated in cases where biochemical control is not achieved by using other forms of medication, with pegvisomant causing a decrease in IGF-1 by inhibiting the growth hormone receptor. Somatostatin receptor agonists form the main category of pharmacotherapy due to their ability to inhibit growth hormone secretion, while the use of dopamine agonists is usually more targeted, given that they are less effective in many individuals. Paltusotine, an oral form of the somatostatin receptor agonist branded Palsonify, came onto the market in 2025 after being approved by the FDA. This approval provided a once-daily oral form of medication for adults with acromegaly who do not respond to surgery or for whom surgery is not an option.

By Route of Administration, medical laboratory testing is the primary segment for diagnosing acromegaly, where IGF-1 levels are assessed for screening purposes, while growth hormone suppression tests confirm the diagnosis. Similarly, medical imaging is a critical component of evaluation, where MRI is typically used to visualize the pituitary gland and determine the tumor's size and location. Both laboratory tests and imaging are used complementarily, with the former evaluating hormone levels and establishing the diagnosis, while the latter determines the tumor's characteristics. In 2025, FDA trials for paltusotine used IGF-1 levels as the main indicator of biochemical response to treatment. Therefore, medical testing is the cornerstone of evaluating acromegaly, which guides clinicians in the selection of pharmacological interventions.

Acromegaly Treatment Market- Geographical Insights

North America remains leading market due to the presence of well-established endocrine therapeutics, regulatory activity, specialized care, and commercialization of innovative modes of therapy. In particular, in September 2025, the FDA approved paltusotine after two pivotal phase III trials were completed across 73 centers and 169 patients in 18 countries. This led to the first FDA-approved once-daily oral therapy for acromegaly. According to Crinetics, the company's sales force contacted more than 95% of key payers and target physicians during the product launch period. This specialty-centric approach helped the company achieve a significant foothold in the market. North America is, therefore, an important base for innovative and convenient modes of therapy.

Europe is an important market due to the presence of well-established treatment centers, a network of specialist physicians, and access to established long-acting somatostatin analogs. According to Ipsen, Somatuline Autogel/Depot was available in nearly 70 different countries worldwide at the end of 2025. The company also reported that 52.1% of the 2025 Somatuline sales were made in North America, thus highlighting the role of Europe as part of a global supply and sales network, rather than a stand-alone regional market. As such, the European market is mainly influenced by the availability of treatment specialties, the use of existing injectable therapies, and the shift towards more convenient approaches.

Acromegaly Treatment Market- Competitive Landscape:

Market competition in the treatment of acromegaly now revolves around mechanisms of action, biochemical control, administration frequency, tolerability, and administration convenience. Long-acting somatostatin receptor agonists will continue to play an important role due to the mechanism involved in biochemical disease control, whereas pegvisomant represents an alternative method of disease management through a growth hormone receptor antagonist. Oral medication administration has gained increasing importance with the FDA approval of Palsonify (paltusotine) in September 2025, an orally administered somatostatin receptor agonist taken on a daily basis. The new option introduces greater administration convenience compared with injectable therapies and may intensify competition regarding adherence, patient preference, treatment switching, and long-term disease management.

Recent Developments:

In September 2025, Crinetics Pharmaceuticals received FDA approval for Palsonify (paltusotine) for the treatment of acromegaly in adults who are unsuitable for surgery or have had an inadequate response to surgery. The new therapy was the first once-daily oral treatment for acromegaly in the United States, differentiating itself through the convenience of administration.

In November 2025, Crinetics announced that Palsonify had been launched in the U.S., with the company's field force having engaged with over 95% of key care providers. Early market feedback suggested that the product was being adopted by both switchers and new users, providing commercial validation for the oral formulation

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ACROMEGALY TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Novartis AG
  • Ipsen Biopharmaceuticals, Inc.
  • Pfizer Inc.
  • Recordati S.p.A.
  • Chiesi Farmaceutici S.p.A.
  • Crinetics Pharmaceuticals, Inc.
  • Camurus AB
  • Ionis Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Wockhardt Ltd.
  • Dauntless Pharmaceuticals
  • GlaxoSmithKline plc
  • Cipla Ltd.
  • Others

GLOBALACROMEGALY TREATMENT MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2020 - 2033

  • Growth Hormone Receptor Antagonists
  • Somatostatin Analogs
  • Dopamine Agonists
  • Others

GLOBAL ACROMEGALY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033

  • Injectable
  • Oral

GLOBAL ACROMEGALY TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2020 - 2033

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

GLOBAL ACROMEGALY TREATMENT MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2020 - 2033

  • Drug Therapy
  • Surgery
  • Radiation Therapy

GLOBAL ACROMEGALY TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Denmark
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Taiwan
  • Vietnam
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Iran
  • Qatar
  • Rest of MEA

Table of Contents

1. Acromegaly Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Acromegaly Treatment Market Snippet by Product Type
    • 2.1.2. Acromegaly Treatment Market Snippet by Route of Administration
    • 2.1.3. Acromegaly Treatment Market Snippet by Distribution Channel
    • 2.1.4. Acromegaly Treatment Market Snippet by Treatment Type
    • 2.1.5. Acromegaly Treatment Market Snippet by Country
    • 2.1.6. Acromegaly Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Acromegaly Treatment Key Market Trends

  • 3.1. Acromegaly Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Acromegaly Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Acromegaly Treatment Market Opportunities
  • 3.4. Acromegaly Treatment Market Future Trends

4. Acromegaly Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Acromegaly Treatment Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Acromegaly Treatment Market Landscape

  • 6.1. Acromegaly Treatment Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Acromegaly Treatment Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2025 & 2033 (%)
    • 7.1.2. Growth Hormone Receptor Antagonists
    • 7.1.3. Somatostatin Analogs
    • 7.1.4. Dopamine Agonists
    • 7.1.5. Others

8. Acromegaly Treatment Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
    • 8.1.2. Injectable
    • 8.1.3. Oral

9. Acromegaly Treatment Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2025 & 2033 (%)
    • 9.1.2. Retail Pharmacies
    • 9.1.3. Hospital Pharmacies
    • 9.1.4. Online Pharmacies

10. Acromegaly Treatment Market - By Treatment Type

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Treatment Type, 2025 & 2033 (%)
    • 10.1.2. Drug Therapy
    • 10.1.3. Surgery
    • 10.1.4. Radiation Therapy

11. Acromegaly Treatment Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Acromegaly Treatment Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Acromegaly Treatment Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.3.17. Denmark
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.17.3. Poland Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.3.17.4. Denmark Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.17.5. Denmark Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.3.17.6. Denmark Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.3.18. Rest of Europe
      • 11.3.18.1. Overview
      • 11.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.18.3. Rest of the Europe Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.3.18.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.18.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.3.18.6. Rest of the Europe Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Acromegaly Treatment Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.4.16. Taiwan
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.16.3. Taiwan Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.4.16.4. Taiwan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.16.5. Taiwan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.4.16.6. Taiwan Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.4.17. Vietnam
      • 11.4.17.1. Overview
      • 11.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.17.3. Vietnam Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.4.17.4. Vietnam Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.17.5. Vietnam Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.4.17.6. Vietnam Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.4.18. Rest of APAC
      • 11.4.18.1. Overview
      • 11.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.18.3. Rest of APAC Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.4.18.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.18.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.4.18.6. Rest of APAC Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Acromegaly Treatment Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Acromegaly Treatment Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.6.14. Iran
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.14.3. Iran Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.6.14.4. Iran Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.14.5. Iran Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.6.14.6. Iran Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.6.15. Qatar
      • 11.6.15.1. Overview
      • 11.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.15.3. Qatar Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.6.15.4. Qatar Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.15.5. Qatar Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.6.15.6. Qatar Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)
    • 11.6.16. Rest of MEA
      • 11.6.16.1. Overview
      • 11.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.16.3. Rest of MEA Market Size and Forecast, By Product Type, 2020 - 2033 (US$ Million)
      • 11.6.16.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.16.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
      • 11.6.16.6. Rest of MEA Market Size and Forecast, By Treatment Type, 2020 - 2033 (US$ Million)

12. Key Vendor Analysis- Acromegaly Treatment Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Novartis AG
    • 12.2.2. Ipsen Biopharmaceuticals, Inc.
    • 12.2.3. Pfizer Inc.
    • 12.2.4. Recordati S.p.A.
    • 12.2.5. Chiesi Farmaceutici S.p.A.
    • 12.2.6. Crinetics Pharmaceuticals, Inc.
    • 12.2.7. Camurus AB
    • 12.2.8. Ionis Pharmaceuticals, Inc.
    • 12.2.9. Sun Pharmaceutical Industries Ltd.
    • 12.2.10. F. Hoffmann-La Roche Ltd.
    • 12.2.11. Merck & Co., Inc.
    • 12.2.12. Wockhardt Ltd.
    • 12.2.13. Dauntless Pharmaceuticals
    • 12.2.14. GlaxoSmithKline plc
    • 12.2.15. Cipla Ltd.
    • 12.2.16. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us